IC
BCAB icon

Ikarian Capital’s BioAtla BCAB Stock Holding History

Ikarian Capital’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,928
Closed -$5.78M – 196
2021
Q3 		$5.78M Buy
3,928
+2,525
+180% +$4.92M 0.41% 59
2021
Q2 		$2.97M Hold
1,403
– – 0.24% 97
2021
Q1 		$3.57M Buy
+1,403
New +$3.6M 0.12% 156

Other funds holding BCAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ikarian Capital's BCAB Position: Q4 2021 in Review

Ikarian Capital sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 3,928 shares — an estimated $5.78M sold.

Ikarian Capital first reported a position in BCAB in Q1 2021 and held it in 3 quarters. The position peaked at $5.78M in Q3 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

  • Ikarian Capital reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
  • Ikarian Capital sold 3,928 BioAtla shares in Q4 2021, an estimated $5.78M.
  • Ikarian Capital first reported a position in BioAtla in Q1 2021 and held it in 3 quarters.
  • Ikarian Capital's BioAtla position peaked at $5.78M in Q3 2021.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.